Abstract: The biological production of beta-hydroxyisovalerate (?HIV) using at least one non-natural enzyme. The non-natural enzyme for the biologically-derived ?HIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural enzyme having one or more modifications of substrate-specificity positions. The non-natural enzyme can be expressed in a microorganism, such as a yeast or bacteria, wherein the microorganism comprises an active ?HIV metabolic pathway for the production of ?HIV. Alternatively, the non-natural enzyme can be a ?HIV synthase used to produce ?HIV in a cell-free environment. The biological derivation of ?HIV eliminates toxic by-products and impurities that result from the chemical production of ?HIV, such that ?HIV produced by a non-natural enzyme prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.

Abstract: Methods, systems, and non-transitory computer readable mediums are disclosed for generating health reports. Pet data associated with an entity is received from one or more data sources. Genetic test results data is received from a genetic test results database. The pet data received from the one or more data sources is analyzed with the genetic test results data received from the genetic test results database using an interpretation logic data structure. A result value associated with the pet data and the genetic test results data is determined based on the analysis. One or more result statements associated with the result value are determined and one or more health reports based on the one or more result statements are generated.

Abstract: The biological production of beta-hydroxyisovalerate (?HIV) using a non-natural microorganism. The non-natural microorganism for the biologically-derived ?HIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural microorganism can host a non-natural enzyme, such as the non-natural enzyme expressed in a yeast or bacteria, wherein the non-natural microorganism comprises an active ?HIV metabolic pathway for the production of ?HIV. The biological derivation of ?HIV eliminates toxic by-products and impurities that result from the chemical production of ?HIV, such that ?HIV produced by a non-natural microorganism prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.

Abstract: This invention relates to collagen biomaterials and methods for manufacturing collagen biomaterials. Method disclosed herein include steps of providing a suspension of insoluble collagen fibres, providing a layer deposition interface and applying an electric field across the suspension to cause electrophoretic deposition of the insoluble collagen fibres at the layer deposition interface. Biomaterials disclosed herein include a layer comprising an array of fibres of collagen, and a layered composite material comprising at least first and second fibrous layers each comprising an array of fibres of collagen, and a shape adapting layer sandwiched between the first and second fibrous layers. Biomaterials as described herein may be useful in a range of tissue engineering and other applications.

Abstract: A multi-layer sleeping compartment for an aircraft is provided in order to more comfortable accommodate passengers to recline and sleep. The multilayer compartment houses a plurality of sleeping pods arranged either side of an entrance, and the sleeping compartment is generally aligned with a longitudinal axis of the aircraft. Further the pods may be booked for session times during the normal flight of an aircraft.

Abstract: The biological production of beta-hydroxyisovalerate (?HIV) using a non-natural microorganism. The non-natural microorganism for the biologically-derived ?HIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural microorganism can host a non-natural enzyme, such as the non-natural enzyme expressed in a yeast or bacteria, wherein the non-natural microorganism comprises an active ?HIV metabolic pathway for the production of ?HIV. The biological derivation of ?HIV eliminates toxic by-products and impurities that result from the chemical production of ?HIV, such that ?HIV produced by a non-natural microorganism prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.

Abstract: Embodiments herein are directed to egg replacement compositions, egg replacement emulsions, liquid eggs, liquid egg formulations, or egg replacement formulations and the use of each in a variety of food products, wherein the egg replacement compositions, egg replacement emulsions, liquid eggs, liquid egg formulations, or egg replacement formulations possess one or more functional properties similar to a natural egg.

Abstract: Various methods of additive layer manufacturing, and objects obtainable by such manufacturing, are disclosed. In particular, there is provided a method of additive layer manufacturing comprising depositing a layer of a material on a surface, and controlling the deposition to vary a material property of the material within the layer. There is also provided a method of additive layer manufacturing comprising depositing at least one layer of material on a sacrificial layer, the layer of material having a thickness of 400 microns or less, wherein the sacrificial layer is located on a base surface.

Abstract: A multi-layer sleeping compartment for an aircraft is provided in order to more comfortable accommodate passengers to recline and sleep. The multilayer compartment houses a plurality of sleeping pods arranged either side of an entrance, and the sleeping compartment is generally aligned with a longitudinal axis of the aircraft. Further the pods may be booked for session times during the normal flight of an aircraft.

Abstract: Embodiments herein are directed to egg replacement compositions, egg replacement emulsions, liquid eggs, liquid egg formulations, or egg replacement formulations and the use of each in a variety of food products, wherein the egg replacement compositions, egg replacement emulsions, liquid eggs, liquid egg formulations, or egg replacement formulations possess one or more functional properties similar to a natural egg.

Abstract: The biological production of beta-hydroxyisovalerate (?HIV) using at least one non-natural enzyme. The non-natural enzyme for the biologically-derived ?HIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural enzyme having one or more modifications of substrate-specificity positions. The non-natural enzyme can be expressed in a microorganism, such as a yeast or bacteria, wherein the microorganism comprises an active ?HIV metabolic pathway for the production of ?HIV. Alternatively, the non-natural enzyme can be a ?HIV synthase used to produce ?HIV in a cell-free environment. The biological derivation of ?HIV eliminates toxic by-products and impurities that result from the chemical production of ?HIV, such that ?HIV produced by a non-natural enzyme prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.

Abstract: The biological production of beta-hydroxyisovalerate (?HIV) using a non-natural microorganism. The non-natural microorganism for the biologically-derived ?HIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural microorganism can host a non-natural enzyme, such as the non-natural enzyme expressed in a yeast or bacteria, wherein the non-natural microorganism comprises an active ?HIV metabolic pathway for the production of ?HIV. The biological derivation of ?HIV eliminates toxic by-products and impurities that result from the chemical production of ?HIV, such that ?HIV produced by a non-natural microorganism prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.

Abstract: Embodiments herein are directed to methods for preparing and compositions containing microalgae biomass. Described herein are, for example, methods of preparing a microalgal flour that involve culturing microalgae, concentrating the microalgae into a microalgal biomass sludge, washing the microalgal biomass sludge, adjusting the pH of the microalgal biomass sludge, and drying the microalgal biomass sludge to produce the microalgal flour. Also disclosed are food products supplemented with microalgae biomass, including for example microalgal flour, a protein concentrate, or a protein isolate.

Abstract: This invention relates to collagen biomaterials and methods for manufacturing collagen biomaterials. Method disclosed herein include steps of providing a suspension of insoluble collagen fibres, providing a layer deposition interface and applying an electric field across the suspension to cause electrophoretic deposition of the insoluble collagen fibres at the layer deposition interface. Biomaterials disclosed herein include a layer comprising an array of fibres of collagen, and a layered composite material comprising at least first and second fibrous layers each comprising an array of fibres of collagen, and a shape adapting layer sandwiched between the first and second fibrous layers. Biomaterials as described herein may be useful in a range of tissue engineering and other applications.

Abstract: A method for providing mobile subscription content access is disclosed. Initially, subscription contents are stored in a server. The subscription content can be accessed via any terminal coupled to the server by a communication link. In response to an access to any of the subscription contents on an encrypted subscription channel via a terminal, a determination is made as to whether or not a valid receiver is found in the proximity of the terminal. If a valid receiver is found in the proximity of the terminal, an encryption/decryption key is transferred to the valid receiver. With the encryption/decryption key, the subscription contents on an encrypted subscription channel can be accessed via the terminal and the valid receiver.